(September 30, 2016, 9:24 AM EDT) -- WASHINGTON, D.C. — Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) ask the U.S. Supreme Court in a Sept. 19 petition whether the filing of an abbreviated new drug application (ANDA) by a generic pharmaceutical manufacturer is sufficient to subject them to specific personal jurisdiction in any state where they might market the drug (Mylan Pharmaceuticals Inc. and Mylan Inc. v. Acorda Therapeutics Inc. and Alkermes Pharma Ireland Ltd., No. 16-360, U.S. Sup.).

(Petition for writ of certiorari available. Document #78-161003-006B.)

Acting on interlocutory appeal, the...